A slight trend toward mild, drug-induced decreases in orthostatic BP and moderate increases in orthostatic heart rate were observed, but there was no clear dose-dependency.
← all excerpts
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
1
—
—